ISSN 2349-7203
IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
HUMAN

Human Journals
Review Article
June 2021 Vol.:21, Issue:3
© All rights are reserved by M. S. Charde et al.

Degradation Profiling by RP- HPLC: A Review

D. D. Masne, K. P. Jatte, M. A. Khachane, R. D. Chakole, M. S. Charde*

Post Graduate Department of Pharmaceutical Chemistry
Government College of Pharmacy, Vidyanagar, Karad, Dist.: Satara Pin- 415124, Maharashtra, India.

Submitted: 20 May 2021
Accepted: 26 May 2021
Published: 30 June 2021

www.ijppr.humanjournals.com

Keywords: HPLC, Stability Indicating Assay Methods (SIAM), Forced degradation

ABSTRACT

High-performance liquid chromatography (HPLC) is widely used for the quantitative as well as qualitative analysis of drug products and is used for determining drug product stability as it is the most accurate method. Stability indicating HPLC methods are mainly used to separate various drug-related impurities, degradation products which are formed during the synthesis or manufacturing of drug product. This article discusses the plan of action and issues related to the development of a stability-indicating HPLC system for drug substances. Several key chromatographic factors were assessed to optimize the detection of all potentially relevant degradants. The method should be carefully examined for its ability to differentiate the primary drug components from the impurities. It's necessary to carry out forced degradation studies of new chemical entities and drug products. The study helps develop and demonstrate the specificity of such stability-indicating methods. Practical recommendations are provided at every stage of drug development which will help to avoid failures.

INTRODUCTION:

High-Performance Liquid Chromatography (HPLC) is an analytical technique to separate, identify, and quantify elements in a mixture. Most of the improvement of HPLC technique development has been targeted at the improvement of HPLC conditions. Forced degradation or accelerated degradation may be a method whereby the natural degradation rate product or material is exaggerated by the application of extra stress. Forced degradation or stress testing is undertaken to demonstrate specificity once developing stability-indicating ways, significantly once very little info is accessible regarding potential degradation product. These studies additionally give information regarding the degradation pathways and degradation products that would kind throughout storage. (1)

The chemical stability of prescribed drugs may be a matter of nice concern because it affects the security and effectiveness of the drug product. The federal agency and ICH guidance state the necessity of stability testing information belowstand|to know|to grasp} however the standard of a drug substance and drug product changes with time under the influence of assorted environmental factors. Data of the steadiness of molecule helps in choosing correct formulation and package likewise as providing correct storage conditions and period that is crucial for restrictive documentation. Forced degradation may be a method that involves degradation of the drug product and drug substances at conditions a lot of severe than accelerated conditions and so generates degradation product which will be studied to see the steadiness of the molecule. (2)

According to An federal agency steerage document, a stability-indicating technique is "a valid quantitative analytical procedure which will find the changes with time within the pertinent properties of the drug substance and drug product. A stability-indicating technique accurately measures the active ingredients, while not interference from degradation product, method impurities, excipients, or alternative potential impurities."(3)

International Conference on Harmonization (ICH) tips, clearly mandated Stability-Indicating Assay technique (SIAM) that area unit used for the analysis of the stability of samples in pharmaceutical business. the rules expressly need conduct of forced decomposition studies below a spread of conditions, like pH, light, oxidation, dry heat, etc., and separation of drug from degradation product. The strategy is anticipated to permit analysis of individual degradation products. (4)

The objective of forced degradation studies:

Forced degradation studies are meted out to attain the subsequent purposes:

- Establishment of degradation pathways of drug substances and drug products.
- Differentiation of degradation product which is associated with drug product from people who are generated from non-drug product in a very formulation.
- Elucidation of the structure of degradation product.
- Determination of the intrinsic stability of a drug substance in the formulation.
- To reveal the degradation mechanisms like a chemical reaction, oxidation, thermolysis, or photolysis of the drug substance and drug product.
- Establishment of stability-indicating nature of a developed technique.
- To perceive the chemical properties of drug molecules.
- Generation of a lot of stable formulations.
- To supply degradation profile just like that of what would be ascertained in a very formal stability study below ICH conditions.
- To solve stability-related issues

HUMAN



Vital Applications of the Forced Degradation Study:

Forced degradation may be a crucial analytical study for the event of stability-indicating ways to be employed by pharmaceutical corporations as a part of restrictive submissions to the government agency. a number of the applications of the studies are:

1. To develop and validate stability-indicating ways as per ICH tips.
2. To spot structure and toxicity and to line up the specification of degradants or impurities.
3. To propose a period of the product while not period stability data.
4. To optimize formulations and to pick out placebos for drug products to avoid interference.
5. To justify method connected impurities or degradation product.
6. To support identification of root cause throughout out-of-specification (OOS)/lab investigations.
7. To accompany drug computer files and ANDA/NDA and IND submissions to the government agency. [8]

Selection and Procedures of Forced Degradation Conditions:

Time to perform forced degradation is vital for the development of the latest drug substance and new drug product. As per FDA tips stress testing ought to be performed in phase III of the regulative submission method. As per ICH tips, common trade follow forced degradation is performed in numerous stress conditions of pH like acid, alkali, peroxide, thermal and wet and UV in conjunction with an impact sample to work out the stability of drug substance. the strain studies ought to be conducted in a single batch and results ought to be summarized and submitted to an annual report. It's counseled to conduct stress testing in an early run or trial phase in clinical trial {clinical test} of clinical trial and may be conducted on drug substance to get spare time for identifying degradation product and structure elucidation furthermore as optimizing the strain conditions.

There are not any industrial tips regarding what proportion degradation ought to be achieved; but, per current industrial practices, five to thirty p.c degradation ought to be achieved in anybody of the applied stress conditions. The aim of the degradation to be achieved through

stress testing is to mimic the room temperature stability conditions. In cases wherever higher or lower degradations are discovered, the conditions or concentrations of the chemical agent ought to be optimized. Mass balance ought to be incontestable throughout the degradation study and it ought to be around one hundred pc, taking into thought margins of analytical errors. All the degradants/impurities should be calculated throughout mass balance evaluations.

During the forced degradation study, any batch that may not be part of regulative submission will be used. Within the case of a drug product, if multiple strengths are offered with similar placebos and different amounts, the strength that has the highest magnitude relation of placebo vs. active pharmaceutical ingredient (API) ought to be used. Wherever placebos are different, and then forced degradation of all the strengths should be incontestable. Throughout the drug product degradation study, each placebo and API should be incontestable to spot actual degradation pathways. Wherever placebos are different for various strengths of drug product, then all the placebos ought to be thought of for the degradation study. The following (Table 1) are the stressed degradation conditions as per current industrial practices and accepted by the FDA throughout DMF/ANDA/NDA and IND submissions for regulative approval.

Table No. 1: stress degradation conditions as per industrial practices.

Degradation Type	Concentration of Reagent	Conditions to be applied	Time	Remarks
Acid	5N HCl	80° C	1 hour	Concentration, condition, and time can be changed to optimize degradation.
Alkali	5N NaOH	80° C	1 hour	
Peroxide	10% H_2O_2	80° C	1 hour	
Heat/Thermal	80°C	80° C	1 hour	
UV	Expose under UV light at 254 nm wavelength.	Ambient temperature.	24 hours	Time can be changed to optimize degradation.
Control	NA	NA	NA	NA

Degradation can be done in either solid or liquid form, but it's best to do it in liquid form with the diluents/mobile process to get a consistent result. To shorten the time of a degradation analysis, harsh conditions (i.e., high reagent concentration with high temperature) may be used to start it. In cases where there is a deterioration of more than 30%, milder conditions should be used, such as decreasing the temperature and reducing the reagent concentration. The conditions of degradation must be optimized to meet a goal based on the initial degradation outcome. To prolong the shelf life of the chromatographic column, the pH should

be changed to about 7.0 to prevent acid and alkali degradation. If none of the above conditions show signs of deterioration, if degradation is not found in any of the above conditions, various reagents and conditions, such as H_2SO4, Zn, and others, may be used. There are a few molecules that do not degrade under certain conditions and are therefore referred to as rock-stable molecules. During a stability analysis, this type of molecule will not produce any additional impurities or degradation peaks.[1, 9]

Development of validated SIAMs that is likely to meet regulatory requirements:

During the forced degradation study, a lot of degradation products may be generated than expected throughout the command. Degraded samples, at the side of known impurities, are employed to develop the analytical methodology. These samples represent the worst-case state of affairs and every one of the peaks (main peak, degraded peaks, and known impurities) should be separated from one another. In cases wherever the analytical methodology isn't able to separate all the peaks, the strategy has to be redeveloped to attain separation of all the peaks. Once Associate in Nursing analytical methodology is developed that's capable of separating all the peaks from degraded samples, it suggests that this methodology is capable of analyzing all the steadiness samples and, therefore, this analytical methodology is going to be thought-about stability-indicating. Methodology validation should be performed to demonstrate that the analytical methodology is appropriate for its meant purpose (refer to ICH pointers Q2 (R1) Validation of Analytical Procedures). The forced degradation info can even facilitate with determinant the foundation cause throughout OOS/lab investigations throughout the sample analysis, e.g., if any sudden peaks area unit ascertained throughout the sample analysis that wasn't ascertained throughout any forced degradation condition, it will be complete that the height is thanks to contamination, either throughout the producing method or throughout the analysis. HPLC has been widely used. It’s gained quality instability studies thanks to its high-resolution capability, sensitivity, and specificity. Non-volatile, thermally unstable, or polar/ionic compounds can even be analyzed by this method. Therefore, most of the SIAMs are established exploitation HPLC. [4, 8]

Though the necessities concerning Siam are corn enter restrictive documents, information on the fundamental steps to be followed for the event and validation of stability-indicating strategies are neither provided within the restrictive pointers nor the pharmacopeias. Therefore, the sensible steps concerned within the development of Siam’s area unit are mentioned below. It is expected that by following the steps, one ought to be in an exceedingly

position to develop a Siam that will meet the restrictive necessities. Our discussion is often bound towards the development of SIAMs by HPLC because it is found that 85–90% of the strategies reported in the literature area unit by this technique.

Step I: a vital study of the drug structure to assess the seeming decomposition route(s)

This is the primary component whenever one takes up the project on SIAM. Much data will merely be gained from the structure, by the study of the useful teams and different key elements. There are useful cluster classes, like amides, esters, lactase, lactones, etc. that bear chemical reaction, others like thiols, thioethers, etc. bear oxidization, and compounds like olefins, aryl halo derivatives, aryl carboxylic acid acids, and people with aromatic nitro teams, N-oxides bear photodecomposition. Most of the new medicines are congeners of existing drug molecules, and there are only a few new medicines, that originate from fully new leads. For a brand new being, its degradation chemistry is simply postulated supported by the reported behavior of different medicine within the series. For instance, there are quite forty penicillins in clinical apply nowadays and most of them follow an equivalent degradation behavior at the beta-lactam moiety. Most of them follow similar succeeding reactions (Fig 1). Similarly, studies in our laboratory have shown that 3 alpha-adrenergic blockers (prazosin, doxazosin, and terazosin) that have similar parent structures follow an equivalent chemical reaction route involving breakage of the organic compound bond(Figure 2). [10]

Figure No. 1: Degradation behavior of penicillin under hydrolytic condition.

Figure No. 2: degradation behavior of alpha adrenergic blocker drugs.

Step II: a collection of information on physicochemical properties

Before technique development is concerned, it's typically vital to understand numerous chemistry parameters like pKa, log P, solubility, physical property, and wavelength of most of the drugs in question. The data of pKa is very important as most of the pH-related changes in retention occur at pH values at intervals of 1.5 units of the pKa price. The ionization price additionally helps in choosing the pH of the buffer to be employed in the mobile part. The data of log P for the drug and therefore the known degradation product provides sensible insight into the separation behavior possible to be obtained on a specific stationary part. pKa

and logo may be much determined or perhaps in theory calculated mistreatment the business package, like Pallas (Comp drug Chemistry Ltd., Budapest, Hungary), CLOGP (Pamona school, Pamona, USA), etc.

The analysis of the drug or degradation product needs that they're soluble in HPLC compatible solvents within the 1st place. The provision of the solubility knowledge in the binary compound, organic, and normally used HPLC solvents and therefore their mixtures will therefore persuade be helpful within the choice of the sample solvent and the mobile part. Because the HPLC analysis using a UV detector is sometimes dispensed at the wavelength most or a wavelength wherever all elements show sensible absorbance, therefore, the {requirement} to understand the wavelength maxima associate degreed extinction of the drug and degradation product completely different in several solvents and at different pH becomes an absolute requirement. [4, 10]

Step III: stress (forced decomposition) studies

The next step within the development of SIAM is that the conduct of forced decomposition studies to get the degradation product of the drug. The ICH guideline Q1A suggests the subsequent conditions to be employed:

(i) 10 °C increments higher than the accelerated temperatures (e.g. 50 °C, 60 °C, etc.),

(ii) humidity wherever acceptable (e.g. seventy-fifth or greater),

(iii) hydrolysis across a large vary of hydrogen ion concentration values,

(iv) oxidation and

(v) photolysis.

However, the guidelines do not provide details on however hydrolytic, photolytic, and aerobic/oxidative studies have to be compelled to be performed. On the opposite hand, the data is offered in the literature however in a very staggered approach, with suggested approaches differing from each other. A comprehensive document providing steerage on the sensible conduct and problems associated with stress testing below style of ICH prescribed conditions has been revealed of late.

This report from the authors proposes a classification theme and offers call trees to assist within the choice of the proper style of stress condition in a very minimal variety of makes an

attempt. The hydrolytic degradation of a replacement drug in acidic and alkali conditions is studied by refluxing the given drug in 0.1 N HCl/NaOH for 8 hr. If cheap degradation is seen, testing is stopped at this time. However, just in case no degradation is seen beneath these conditions, the drug should be refluxed in acid/alkali of upper strengths and for an extended period. as an alternative, if total degradation is seen once subjecting the drug to initial conditions, acid/alkali strength is decreased in conjunction with a decrease within the reaction temperature. in an exceedingly similar manner, degradation beneath neutral conditions is started by refluxing the drug in water for twelve hrs. Reflux time ought to be enlarged if no degradation is seen. If the drug is found to degrade utterly, each time and temperature of study is decreased. To check oxidization, it's recommended to use peroxide within the concentration varies of 3–30%. The photolytic studies ought to be administrated by exposure to lightweight, mistreatment either a mixture of cool white and ultraviolet fluorescent lamps or one amongst the element and metal salt lamps. Exposure energy ought to be a minimum of one.2 million lx h fluorescent lightweight and two00 W h/m2 actinic ray and if decomposition isn't seen, the intensity ought to be enlarged by 5 times. Just in case still no decomposition takes place, the drug is declared photostable. A minimum of 4 samples ought to be generated for each stress condition, viz. the blank answer keeps beneath traditional conditions, the blank subjected to fret within the same manner because the drug answer, zero time sample containing the drug that is kept beneath traditional conditions and also the drug answer subjected to fret treatment. The comparison of the results of those provides a realistic assessment of the changes. Moreover, it's suggested to withdraw samples at totally different periods for every reaction condition. By doing this, one will get a transparent plan on the quantity of product fashioned, their relative strengths, and whether or not they are unit stable or unstable, ensuing any in the newer product. This data is important in the institution of SIAMs. The studies ought to be initiated at a level of 1 mg/ml. If solubility could be a limitation, a variable amount of methyl alcohol is also accustomed to get a transparent answer, or maybe the testing is done on a suspension. By mistreatment drug concentration of 1 mg/ml, it's sometimes attainable to urge even minor decomposition product within the range of detection. If many degradation product area units are fashioned in several conditions, the SIAMs could involve loads of development work. For this, repeat injections of reaction solutions may well be needed. Therefore, the number of samples subjected to stress studies ought to be insufficient quantity and conjointly enough sample volume ought to be drawn at every amount. The withdrawn sample is kept in cold cupboards to prevent any reaction. The aliquots may well be diluted or neutral before injecting into HPLC. [11, 12]

Degradation conditions

1. Hydrolytic conditions

Hydrolysis is one of the foremost common degradation chemical reactions over the change of pH. The reaction is a chemical change that has decomposition of a matter by reaction with water. Hydrolytic study under acidic and basic conditions involves the chemical process of ionizable practical teams present within the molecule. Acid or base stress testing involves forced degradation study of a drug substance by its exposure to acidic or basic conditions that generate primary degradants in fascinating vary. the choice of the sort and concentrations of acid or base depends on the soundness of the drug substance. A sulphuric acid (0.1–1 M) for acid reaction and hydroxide or potash (0.1–1 M) for the base reaction is recommended as appropriate reagents for reaction. If the compounds for stress testing are poorly soluble in water, then co-solvents may be used to dissolve them in HCl or NaOH. The choice of co-solvent relies on the drug substance structure. Stress testing trial is often started at temperature and if there's no degradation, elevated temperature (50–70°C) is applied. Stress testing mustn't exceed over seven days. The degraded sample is then neutralized using appropriate acid, base or buffer, to avoid any decomposition.

2. Oxidation conditions

HUMAN

Hydrogen peroxide is widely used for the chemical reaction of drug substances in forced degradation studies however alternative oxidizing agents like metal ions, oxygen, and radical initiators (e.g., azo-bis-isobutyronitrile, AIBN) can even be used. Choice of associate oxidizer, its concentration, and conditions depends on the drug substance. It's reported that subjecting the solutions to 0.1–3% oxide at neutral pH scale and temperature for 7 days or up to a most 20% degradation might doubtless generate relevant degradation product. The oxidative degradation of drug substances involves an associated 'electron transfer mechanism' to create reactive anions and cations. Amines, sulfides, and phenols are liable to electron transfer chemical reactions to form N-oxides, hydroxylamine, sulfones, and sulfoxide. The functional group with labile H like group carbon, group carbon, and tertiary carbon or α-positions concerning hetero atom is liable to chemical reaction to create hydroperoxides, hydroxide, or organic compound.

3. Photolytic conditions

The exposure stability testing of drug substances ought to be evaluated to demonstrate that light exposure doesn't lead to unacceptable change. Photostability studies are meant to be performed to get primary degradants of a drug substance by exposure to ultraviolet radiation or fluorescent conditions. ICH guidelines have suggested conditions for photostability testing. Samples of drug substance, solid/liquid drug product allows being exposed to a minimum of 1.2 million lx h and a 200 W h/m2 light-weight. The foremost ordinarily accepted wavelength of lightly within 300– 800 nm to cause photolytic degradation. The most illumination suggested is 6 million lx h. Photolytic stress conditions will induce exposure to the chemical reaction by a free radical mechanism. Functional groups like carbonyls, nitroaromatic, N-oxide, alkenes, aryl chlorides, weak C–H and O–H bonds, sulfides, and polyenes are likely to introduce drug sensibility.

4. Thermal conditions

Thermal degradation (e.g., dry heat and wet heat) ought to be carried out in a lot of strenuous conditions than suggested ICH Q1A accelerated testing conditions. Samples of solid-state drug substances and drug products got to be exposed to dry and wet heat, whereas liquid drug products got to be exposed to dry heat. Studies could also be conducted at higher temperatures for a shorter amount. Effect of temperature on thermal degradation of a substance is studied through the Svante August Arrhenius equation:

k ¼ AeEa=RT

where,

k is restricted reaction rate,

A is frequency issue,

Ea is the energy of activation,

R is constant (1.987 cal/deg mole) and

T is temperature.

Thermal degradation study is meted out at 40–80 °C.[1, 13, 14, 15]

LIMIT FOR DEGRADATION:

The question of what proportion degradation is decent has been the subject of many discussions amongst pharmaceutical scientists. Degradation of drug substances between 5%-20% has been accepted for validation of chromatographic assays. As per some pharmaceutical scientists, 10% degradation is perfect to be used in analytical validation for small pharmaceutical molecules for which acceptable stability limits of 90% of label claim is common. Others suggested that drug substance spiked with a combination of a degradation product is used to challenge the ways utilized for observing stability of drug product. No such limits for physiochemical changes, loss of activity, or degradation throughout shelf life are established for individual sorts or groups of the biological products.

It is not necessary that forced degradation would end in a degraded product. The study is terminated if no degradation is seen when a drug substance or drug product has been exposed to stress conditions than those conditions mentioned in the accelerated stability protocol. This is indicative of the stability of the molecule is underneath the test. Over-stressing of a sample might result in the formation of secondary degradation product that might not be seen in normal shelf life period of stability studies and under-stressing might not generate degradation product. Protocols for the generation of product-related degradation might take issue for drug substance and drug product due to variations in matrices and concentrations. It's suggested that a maximum of 14 days for stress testing in resolution [max of 24hrfor oxidative (aerobic tests)] provide stressed samples for method development. [1,3,16]

Step IV: Preliminary separation studies on stressed samples

The stress samples thus obtained are subjected to preliminary analysis to check the quantity and types of degradation product shaped below numerous conditions. For doing this, the best approach is to start with a reversed-phase octadecyl column, ideally a brand new or one in a very healthy condition. Well-separated and good quality peaks at the starting time give higher confidence attributable to the unknown nature of the product shaped throughout stressing. It ought to be most popular to use water– methyl alcohol or water–acetonitrile because the mobile introduces the initial stages. The employment of buffers isn't instructed at this stage as a result of as is often needed, one will extend the buffer-free mobile phase to preparative LC or LC-MS studies. Between methanol and acetonitrile, methanol should be preferred due to its low cost. The information from previous studies on the development of assay method for

the drug can also be applied here and the organic modifier can be chosen accordingly. The solvent might be changed if the peak shape or separation problems are seen.

Initially, the water: organic modifier ratio relation may be fixed at 50:50 or maybe fittingly changed therefore to get the capacity factor of around 5–10 for the drug. As degradation products from medicine are typically polar (of course with exceptions), pushing the drug peak to mention 15 min or somewhat additional in a very 25-cm column, may end up in separation of many degradation products, once shaped. The retention time may be altered by ever-changing the mobile section however it mustn't be pushed so much, as it may increase resolution (and ruggedness), however oppositely the peaks change shape leading to a decrease insensitivity. Normally, the entire run time ought to be 2.5 times over the drug peak, a minimum of in initial studies, and this long amount is to indicate up any peak that will wash later to the drug peak. The detection wavelength may be set, supported by the study of the spectral behavior of degraded samples, as mentioned earlier. The injection volume and therefore the rate may be fittingly adjusted supported the length of the column. Using these natural HPLC process conditions, one should follow the changes altogether in the strain samples, at varied periods. The results ought to be critically compared with the blank solutions injected in a very similar manner. It ought to be discovered whether or not the autumn in drug peak is quantitatively followed by a corresponding rise within the degradation product peaks. It mustn't be taken as a surprise if the height rise isn't in correspondence to the fall of the drug. This is often a result of the drug and its product can have completely different extinction values. Even there may be things wherever no extra peak seems within the recording, apart from the drug. A typical example is given in Figure 3.



Figure No. 3: Degradation of metronidazole in acidic conditions under light: (a) initial sample (b) 3-day sample (c) 12-day sample

The drug fall is seen, however with no extra peak rise. Such a state of affairs will either arise because of the formation of non-chromophoric products or because of the decomposition of the drug to low relative molecular mass fractions. In such things, the detection at multiple wavelengths or the utilization of LC-MS becomes necessary. Typically the absence of a synchronal rise in degradation product peak may also result in the total quality of the merchandise within the reaction solutions, which might be confirmed through physical observation of the reaction mixture. In such a case, the merchandise is often separated and might be injected one by one using a solvent in which it's soluble to seek out its retention time (RT) within the recording. Later, throughout the ultimate methodology development changes are often created in the mobile section or the sample solvent to possess the merchandise shown up within the recording. Even the absence of degradation peak will happen once the entity is discolored and shows no actinic radiation absorption at a specific wavelength at that the analysis has been conducted. This may be verified by easy observation of whether or not any color has developed within the reaction resolution. Here conjointly appropriate adjustments within the wavelength of study are often created for the merchandise to look within the recording.

Step V: final method development and optimization

After preliminary chromatographic studies, the RT and relative retention times(RRT) of all product shapes ought to be tabulated for every reaction condition. Special attention is then paid to those elements whose RT or RRT are near to one another.

Sample Preparation for Technique Development:

It is difficult to obtain actual representative samples within the early stage of development. Stressing the API generates the sample that contains the product likely to generate beneath the most realistic storage conditions that are successively used to develop the SIM. Every forced degradation sample ought to be analyzed by the victimization of the preliminary HPLC conditions with an appropriate detector, most ideally PDA detector. whereas the everyday dosage form which is typically used like-solid (tablet/capsule), solid (ointment/cream), or solution (cough syrup/ ophthalmic solution)- utilizes a solid-phase extraction (SPE) for sample preparation, particularly for bio-samples and as another to liquid-liquid extractions in several U.S. Environmental Protection Agency (EPA) method. [1]

Developing Separation- Stability-indicating chromatographic condition:

In choosing initial chromatographical conditions for a SIM of a brand new entity, most vital is to make sure that degradants obtained are in solution form, which then separated, and detected. To the current result, diluents of 1:1 water: organic solvent could be a sensible starting point because it can increase the solubility of most connected/related materials and also correct disintegration of solid dosage forms. The second step is to get separation conditions that permit the determination of several distinct peaks as potential from the set of test samples. The foremost common separation variables embody the type of solvent, pH of mobile phase, ion concentration, column kind, and temperature. [12]

Solvent type:

The beginning solvent designated for a given separation may be chosen by matching the relative polarity of the solvent to it the sample.

1. If the sample seems at the solvent front then the solvent is just too polar to permit the adsorbent to retard the sample. Move from a solvent to a higher-up (lower polarity) on the scale.

2. Conversely if the sample doesn't seem in a reasonable time move to a solvent or solvent blend lower down (higher polarity) on the scale. Solvent type (methanol, acetonitrile, and tetrahydrofuran) can affect solubility. The selection of solvent relies on the solubility of the analyte and buffer used.

Mobile phase pH:

Most pharmaceutical compounds contain ionizable functional groups such as amino, pyridine, and carboxylic acid. Introducing new packing material which is stable over a wide range of pH up to 12 allows for wider applicability of a mobile phase pH as a retention parameter or selectivity adjustment parameter. Optimization of the mobile phase can be maximized in combination with bonded phase optimization (i.e., substituting C18/C8 with cyano or phenyl). A goal for the band spacing of a solute (K') should be in the range of 4 to 9 and a run time of about 15 - 20 minutes for much routine product release or stability runs.

Role of the Column and Column Temperature (Selecting an HPLC Column):

The column is the heart of an HPLC system. The best result on the resolution of analytes throughout method development can be achieved by changing the column. Selecting the simplest column for application needs consideration of stationary phase chemistry, retention capability, particle size, and column dimensions. The 3 main parts of the HPLC column are the hardware (column housing), the matrix, and the stationary phase. Generally, trendy reverse part HPLC columns are created by packing the column housing (hardware) with spherical colloid beads that are coated with the hydrophobic stationary part. The stationary phase is introduced to the matrix by reacting a chlorosilane with –OH group on the silica gel colloid surface.

Types of columns used for normal phase: chromatography embrace underivatized silicon dioxide, nitrile, amino (or aminopropyl), glycerin, and nitro columns. Chiral separation is typically performed underneath normal phase chromatography. Since extremely polar and ionic compounds are maintained on normal phase columns, a guard column or colloid sample purification ought to be used to extend the column life. In reverse phase natural action the stationary phase is non-polar and therefore the mobile phase is polar, inflicting polar peaks to elute previous to non-polar peaks. Common stationary phases are C4 (butyl), C8 (MOS), C18 (ODS), nitril (cyanopropyl), and phenyl (phenyl propyl) columns.

Column Temperature:

Temperature can affect the selectivity of column hence to control column temperature is important for long-term method reproducibility. Temperature ranging from 30-40°C is normally sufficient for good reproducibility. In HPLC, the temperature has been an overlooked operational parameter, and the potential benefits of increased column temperatures, particularly increase kinetic and transport properties, which are based on the reduction in viscosity of mobile phase and increase of the analyte diffusivity at a higher temperature.

Peak Purity:

An essential requisite of a separate analysis is that the ability to verify the purity of the separated species, that is, to confirm that no co-eluting or co-migrating impurity contributes to the peak response. The confirmation of peak purity ought to be performed before quantitative info from a chromatographic or electrophoretic peak is employed for any

calculations. Peak purity (or peak homogeneity) analysis of the most peak, to assess for the presence of impurities below the main peak, is an important part of the validation of a SIM.

Method Optimization:

To get better sensitivity after separation the method is optimized. The mobile phase and stationary phase compositions need to be taken under consideration. It is necessary to note that the optimization of mobile phase parameters is always considered first as this is much easier and convenient as compared to stationary phase optimization. To reduce the number of the trial involved, only the parameters that are likely having a significant effect on selectivity in the optimization is to be examined. Primary control variables (factors) within the optimization of liquid chromatography (LC) strategies are the different components of the mobile phase which determine acidity, solvent strength, gradient, flow rate, temperature, sample amounts, injection volume, and diluents solvent type. This is used to find the required balance between resolution and analysis time after satisfactory selectivity has been achieved. The parameters involved are column dimensions, column-packing particle size, and flow rate. These parameters may be altered without affecting capacity factors or selectivity. [1, 18, 19]

Step VI: identification and characterization of degradation products, and preparation of standards

HUMAN

Before validating a SIAM, it is important to determine the drug degradation products and arrange for their standards. These are a necessity to establish the specificity/selectivity of the method. The work on this aspect can be initiated as an idea on the nature and number of degradation products generated under different degradation conditions is obtained from preliminary separation studies. To detect the resolved products, a conventional way is to isolate them and determine the structure through spectral (MS, NMR, IR, etc.) and elemental analysis. However, this approach is tedious and requires more time when multiple degradation entities are formed. Against it, the trending approach is to use hyphenated LC techniques connected with mass spectrometry. This strategy integrates into a single instrument approach, analytical HPLC, UV detection, tandem mass spectrometry (LC-MS-MS), and full scan mass spectrometry (LC-MS) and provides a clear idea on the identity of resolving components. LC-MS or LC-MS-MS is employed to obtain molecular weight, fragmentation information, and detailed structural information is obtained through LC-NMR analysis. The integrated approach gives rapid identification of several degradation products at a single time. Regarding the product standards, a direct way is to obtain them from

commercial sources. However, in case they are not available commercially, they have to be either separated from the degradation reaction solutions or synthesized in the laboratory. Identifying reaction conditions is the best way to isolate the product. If the product shows precipitation or crystallization on its own on completion of the reaction, it can be recovered simply. Otherwise, lyophilization of the reaction mixture can be performed directly. If freeze-drying (lyophilization) is done after neutralization of the reaction mixture, the product can be recovered by extraction with dry methanol or with any other suitable dry solvent. The recovery can also be done by selective extraction with an organic solvent after acidification, neutralization, or basification of the solution, depending upon its initial pH. Subsequently, the extraction solvent can be evaporated to recover the product. One must check whether the product of interest decomposes/degrade further on changing pH. When no condition is identified where the product is generated quantitatively into a single entity, then the product can be separated from the mixture by selective solubility-based extraction, preparative TLC, or preparative HPLC. Normal column chromatography, medium-pressure liquid chromatography, flash chromatography, chromatin, etc. can also be used. If the identity of the products has been previously established through sophisticated LC-MS and/or LC-NMR studies, the desired molecules can be synthesized, characterized and the presence confirmed through spiking in the degraded sample. The synthesis route has the benefit that it results in a neater product that can be obtained through isolation. (4)

Step VII: validation of SIAMs

Method validation

Accuracy: It is an assessment of the difference between the measured value and real value. It is the closeness of test results obtained by that method to that of true value.

Accuracy is determined in four ways:

1. By analyzing a sample of known concentration and comparing measured value to true value.

2. To compare test results from the new method with the result from the existing alternate well-characterized procedure that is known to be accurate.

3. Based on recovery of known amounts of the analyte, is performed by spiking analyte in blank matrices.

Spiked samples are prepared in triplicate at three levels over a range of 50–150% of the target concentration for assay methods. For impurity methods, spiked samples are prepared in triplicate at three levels over a range that covers the expected impurity content of the sample, such as 0.1–2.5% (v/w). For determining the analyte levels in the spiked samples, the same quantitation procedure will be used as in the final method procedure (i.e., same number and levels of standards, the same number of sample and standard injections, etc.). Then percent recovery should be calculated.

4. It is used to determine the recovery of the spiked analyte. If it is not possible to prepare a blank sample matrix without the presence of the analyte then this approach is used. for example, with lyophilized material in which the speciation in the lyophilized material is significantly different when the analyte is absent. Accuracy criteria for an assay method (FDA) are that the mean recovery will be 100% at each concentration over the range of 80–120% of the target concentration. For an impurity method, the mean recovery will be within 0.1% absolute of the theoretical concentration or 10% relative, among them the greater one is selected, for impurities in the range of 0.1–2.5% (v/w).

Precision: The precision of the analytical method is the degree of agreement among individual test results when the method is applied repeatedly to multiple sampling of a homogeneous sample. Precision and accuracy are determined on a case-by-case basis. For a typical related substance method, the RSD of 6 replicates should be > 10%. Accuracy should be 70 % - 130% of theory at the LOQ level.

Specificity: It is the ability to assess unequivocally the analyte in presence of components that may be expected to be present. It should be performed during performing the validation of identification tests, the determination of impurities, and the assay.

Linearity: The linearity of an analytical method is its ability to elicit test results that are directly proportional to the concentration of analyte in a sample within a given range.

Range: Range is the interval between the high and low levels of the analyte understudies. The specified range is normally derived from linearity studies and depends on the intended application of the method. It is established by confirming that the analytical method provides an acceptable degree of linearity, accuracy, and precision when applied to samples containing amounts of analyte within or at extremes of the specified range of the analytical method.

The following minimum specified range should be considered.

1. for the content assay of a drug substance or a finished (drug) product: from 80 to 120% of the product label strength.

2. for content uniformity: covering a minimum of 70 to 130% of product label strength.

3. some methods may be much lower depending on assay need.

Limit of detection (LOD) & Limit of quantitation (LOQ): LOD is the lowest amount of analyte in a sample that can be detected but not necessarily quantitated.

LOQ is the lowest amount of analyte in the sample which can be quantitatively determined with suitable precision and accuracy. The desired method LOQ is related to the ICH reporting limits. If the corresponding ICH reporting limit is 0.1%, the method LOQ should be 0.05% or less to ensure the results are accurate up to one decimal place. However, it is of little value to develop a method with a LOQ much below this level in standard practice because when the method is too sensitive, method precision and accuracy are compromised.

Robustness: It is typically assessed by the effect of small deliberate changes to chromatographic methods on system suitability parameters such as peak retention, resolution, and efficiency. Experimental factors that are typically varied during method robustness evaluation includes

HUMAN

- Age of standards and sample preparations,
- Sample extraction time,
- Variation to pH of mobile phase,
- Variation in mobile phase composition,
- Analysis temperature,
- Flow rate,
- Column lot and manufacturer,
- Type and use of filter against centrifugation. [16]

Validation of analytical ways, in general, has been extensively lined within the ICH pointers Q2A and Q2B, within the Food and Drug Administration steerage, and by USP. There are many alternative reports in the literature, that have reviewed the construct, either generally, or

specifically the validation of chemical analysis, non-chromatographic, and active ways. Various alternative investigations on the development of SIAMs on completely different medicine additionally embrace validation steps, and an essential study of those reports provides a truthful plan on however validation is distributed much. Overall, there are 2 stages within the validation of SIAM's. 1st stage is early within the development cycle once the drug substance is subjected to forced decomposition studies and also the SIAM is established supported the information of drug degradation behavior. the most focus of validation at this stage is on the institution of specificity/selectivity, followed by alternative parameters like accuracy, precision, linearity, range, robustness, etc. the boundaries of detection and quantitation also are determined for degradation entity to assist in the institution of the mass balance. This valid technique finds application within the analysis of stability samples of the bulk drug for the determination of its retest or ending amount. Within the second stage, once the SIAM therefore developed is extended to formulations or alternative matrices, the stress gets restricted to only prove the relevancy of the established validation parameters within the presence of excipients or alternative formulation constituents. Here solely parameters of essential importance like specificity/ property, accuracy, and preciseness are revalidated.

If the SIAM is being developed directly for a formulation, while not involving the majority drug route, then all validation parameters are necessary to be established. The specificity/selectivity of a SIAM is established merely if the degradation chemistry of the drug is thought and also the standards of the merchandise are obtainable. The sole effort concerned than is that the development of a way that separates parts from a physical mixture of drugs and also the degradation product. At this stage, solely peak purity becomes crucial. The height purity is established by a spread of techniques, like PDA detection, absorbance magnitude relation technique, twin wavelength magnitude relation natural process, second-order by-product spectrographic analysis, spectral suppression, spectral overlay, etc. However, not all of these are applicable for online peak purity testing. The foremost in style technique is that the PDA analysis, the principle of that is that the comparison of the spectra of the analyte peak, taken upslope, at the apex, and on the slope. If these spectra don't match then the height is non-homogeneous. A limitation of the PDA observation for peak homogeneity testing is that this method isn't sensitive associate degreed therefore it's unlikely to detect 1 % of interfering part in an analyte peak. An additional limitation is that the high value of the detector. The conventional ultraviolet HPLC detectors currently give coincidental measurements at multiple wavelengths, and a few of them even offer an output

of magnitude relation plots at 2 wavelengths. This method has additionally been promoted for peak purity testing throughout the development of teams. The technique needs an essential choice of measuring wavelengths and is of restricted use wherever the ultraviolet spectrum of the co-eluting part is unknown. The second by-product spectrographic analysis may also be used to assess peak non-homogeneity because it amplifies slight deviations from Gaussian peaks caused by overlapping peaks. Another approach that may be used is that the assortment of fractions from the peak and comparing the results with a considerably completely different chromatographic technique or mass chemical analysis. The development of kinetic plots throughout drug decomposition is extra validation steps that may be accustomed make a sure specific analysis of SIAMs. The accuracy is typically determined by spiking the identified quantity of drug to either the placeboes or the formulations, and determination of % recovery of the drug. However, a stronger technique of crucial accuracy of a SIAM is by spiking the drug in a very mixture of degraded solutions. As a way, because the preciseness cares, there aren't any special necessities for stability-indicating ways and also the same procedure as advocated for traditional assay ways is applied. The one-dimensionality for SIAMs ought to be established at the start within 0–100% because the drug could fall to terribly low concentrations throughout forced decomposition studies. The ultimate validation varies, however, is narrowed primarily based upon the shape during which the drug substance or formulation is distributed. As an example, it's going to vary from eighty to one hundred twenty for the solid bulk drug and stable solid formulations. The vary could also be 50–120% just in case of Injections or alternative formulations wherever the drug is a lot of at risk of degradation. Validation varies for the degradation merchandise throughout stability studies typically ought to vary from 0-20.

The detection and quantitation limits don't seem to be vital for active drug substances, as their concentration is not expected to fall to such a low level in several formulations throughout their period. However, these limits ought to be established for the degradation products. Robustness may also be established for SIAMs in a very similar manner because it is completed in typical ways. [20-22]

Other analytical methods for developing SIM

Potency, purity, and biological activity are additionally taken into consideration for characterization of stability indicating strategies. The choice of tests is product-specific. Stability indicating strategies could embrace numerous strategies like electrophoresis (SDS-

PAGE, immune electrofocusing, Western blot, iso-electro-focusing), high-resolution chromatography (e.g., reversed-phase chromatography, SEC, gel filtration, ion exchange, and affinity chromatography), and amide mapping. The analytical methodology of alternative ought to be sensitive enough to find impurities at low levels (i.e., 0.05% of the analyte of interest or lower) and therefore the peak responses ought to get among a range of detector's linearity. The analytical methodology ought to be capable of capturing all the impurities that square measure shaped throughout proper stability testing at or below ICH threshold limits. Identification of degradation entity and characterization square measure to be performed supported formal stability ends up following ICH needs. Standard strategies (e.g., column chromatography) or combined techniques (e.g., LC-MS, LC–nuclear resonance (NMR)) may be employed in the identification and characterization of the degradation merchandise. The use of those techniques will offer a higher insight into the structure of the impurities that would augment the information house of potential structural alerts for genotoxicity and therefore the management of such impurities with tighter limits. It ought to be noted that structural characterization of degradation merchandise is critical for those impurities shaped throughout formal shelf-life stability studies and higher than the qualification threshold limit.

New analytical technologies that square measure unendingly being developed might be used once it's applicable to develop the stability-indicating methodology. The unknown impurity, that is seen throughout the analysis, pharmaceutical development, stress/degradation studies, and formal stability studies of the drug substances and drug product are often isolated and analyzed by victimization numerous natural process techniques like reversed section high-performance liquid action (RP-HPLC), skinny layer action (TLC), gas action (GC), capillary natural action (CE), capillary natural action (CEC) and super essential fluid action (SFC). a superb combination of combined natural process and spectroscopic technique like HPLC photodiode array ultraviolet detector (DAD), LC-MS, LC–NMR, and GC–MS square measure used once degradants can't be isolated in pure type. HPLC-DAD and LC-MS square measure wont to compare the relative retention time (RRT), UV spectra, mass spectra (MS/MS or MSN). [23, 24, 25, 26]

SUMMARY:

The stability-indicating methodology is an analytical technique that's capable of differentiating between the main active (intact) pharmaceutical ingredients (API) from any degradation (decomposition) product(s) formed under outlined storage conditions throughout

the stability evaluation period. Forced degradation studies are essential for the development of stability-indicating methods and observation of degradants as a part of a validation protocol. Forced degradation studies conjointly give valuable insight into the investigation of degradation entities. The employment of a properly designed and executed forced degradation study can generate a stratified sample that may successively facilitate to development of stability-indicating HPLC methodology. Chromatographic factors ought to be evaluated to optimize the stability-indicating HPLC methodology for the detection of all probably relevant degradants. An applicable sample solvent and mobile phase should afford appropriate stability and compatibility with the component of interest, impurities, and degradants. Therefore, resulting stability-indicating HPLC is fit for finding the degradants and impurities in pharmaceuticals.

ACKNOWLEDGMENT:

The authors of this review article are thankful to the Principal, Government College of Pharmacy, Karad for allowing us to present this paper. We are also thankful to AICTE for providing a research fellowship to complete our research work and convert our research work into publications.

HUMAN

REFERENCES:

1. Shah BP, Jain S, Prajapati KK and Mansuri NY: Stability Indicating HPLC Method Development: A Review. Int J Pharm Res Sci. 3(9); 2978-2988.

2.BlessyMn, Ruchi D. Patel, Prajesh N. Prajapati, Y.K. Agrawal: Development of forced degradation and stability indicating studies of drugs—A reviewJournal of Pharmaceutical Analysis 2014;4(3):159–165

3. G. Ngwa, Forced degradation studies as an integral part of HPLC stability indicating method development, Drug Deliv. Technol. 10 (5) (2010) 56–59.

4. Monika Bakshi and Saranjit Singh: Development of validated stabilityindicating assay methods--critical review. J. Pharm. Biomed. Anal. 2002; 28(6):1011-1040

5. ICH guidelines, Q1A (R2): Stability Testing of New Drug Substances and Products (revision 2), International Conference on Harmonization. Available from: 〈http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm128204.pdf〉, 2003.

6. D.W. Reynolds, K.L. Facchine, J.F. Mullaney, et al., Available guidance and best practices for conducting forced degradation studies, Pharm. Technol. 26 (2) (2002) 48–56.

7. WHO guidelines on stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms, WHO/PHARM/94.565/rev. 1, page 1-13

8. An Introduction To Forced Degradation Studies For Drug Substance & Drug Product ByVinubhai N. Patolia, pharmaceutical online, jan 9,2020

9. FDA Guidance for Industry, INDs for Phase II and III Studies— Chemistry, Manufacturing, and Controls Information, Food and Drug Administration. Available from: 〈http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm070567.pdf〉, 2003.

10. K.A. Connors, G.L. Amidon, V.J. Stella (Eds.), Chemical Stability of Pharmaceuticals, Wiley, New York, 1986.

11. ICH, Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, IFPMA, Geneva, 2000, p. 2..
12. S. Singh, M. Bakshi, Pharm. Tech. On-line 24 (2000) 1–14.
13. A. Gupta, J.S. Yadav, S. Rawat, et al., Method development and hydrolytic degradation study of Doxofylline by RP HPLC and LC–MS/MS, Asian J. Pharm. Anal. 1 (2011) 14–18.
14. K.M. Alsante, T.D. Hatajik, L.L. Lohr, et al., Solving impurity/ degradation problems: case studies, in: S. Ahuja, K.M. Alsante (Eds.), Handbook of Isolation and Characterization of Impurities in Pharmaceutical, Academics Press, New York, 2003, p. 380.
15. S.W. Baertschi, S.R. Thatcher, Sample presentation for photo stability studies: problems and solutions, in: J. Piechocki (Ed.), Pharmaceutical Photostability and Stabilization Technology, Taylor & Francis, New York, 2006, p. 445.
16. Review on stability indicating assay method, Salma S. Quadri*, Lalit V. Sonwane,Bhagwat N. Poul, Sharada N. KamshetteDepartment of Quality Assurance, MSS's Maharashtra College of Pharmacy, Nilanga.
17. Ghulam A. Shabir* Abbott Laboratories, MediSense Products, 14/15 Eyston Way, Abingdon OX14 1TR, UK Journal of Chromatography A, 987 (2003) 57–66
18.Saudagar R.B., Mahale M. M., Stability Indicating HPLC Method Development: A Review, Journal of Drug Delivery and Therapeutics. 2019; 9(3-s):1103-1104
19.K. Huynh-Ba (ed.): Development of Stability indicating methods.Handbook of Stability Testing in Pharmaceutical Development; Springer 2009: 154.
20. ICH, Validation of Analytical Procedures: Methodology. International Conference on Harmonisation, IFPMA, Geneva, 1996.
21. FDA, Guidance for Industry: Analytical Procedures and Methods Validation (Draft guidance). Food and Drug Administration, Rockville, MD, 2000.
22. M.E. Swartz, I.S. Krull, Pharm. Tech. 22 (1998) 104– 119.
23. N.W. Ali, S.S. Abbas, H.E. Zaazaa, et al., Validated stability indicating methods fordetermination of Nitazoxanide in presence of its degradation products, J. Pharm. Anal. 2 (2) (2012) 105–116.
24. V.E. Bichsel, V. Curcio, R. Gassmann, et al., Requirements for the quality control of chemically synthesized peptides and biotechnologically produced proteins, Pharm. Acta Helv. 71 (1996) 439–446.
25.EMA Guideline on the Limits of Genotoxic Impurities, Committee for Medical Products for Human Use (CHMP). Available from:⟨http://www.emea.europa.eu/docs/en_GB/document_library/Scientific guideline/2009/09/WC500002903.pdf⟩, 2007.
26. ICH, Q3A (R2): Impurities in New Drug Substances, International Conference onHarmonization, Geneva.